Abiomed and Impella: historical result in the U.S.A.

Abiomed, consolidated partner of Gada, announced an important achievement in the American healthcare context. The treatment with the Impella percutaneous heart pumps has involved more than 50,000 patients in the U.S.A..

The Impella devices are the only devices recognized as ”safe and effective” by the FDA for the treatment of cardiogenic shock and for High Risk PCI procedures, in which improvement of the ouctomes of patients is a very actual challenge.